Improving the coverage of high priority health services in rural and tribal area of Gujarat
Phase 3
- Conditions
- Health Condition 1: R030- Elevated blood-pressure reading, without diagnosis of hypertensionHealth Condition 2: F99- Mental disorder, not otherwise specifiedHealth Condition 3: D578- Other sickle-cell disordersHealth Condition 4: E118- Type 2 diabetes mellitus with unspecified complications
- Registration Number
- CTRI/2023/07/055643
- Lead Sponsor
- Bill and Melinda Gates Foundation
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
All those living in the study area
Exclusion Criteria
Those deny to take part in the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Primary outcome 1: all-cause mortality & cardiovascular complications event, Primary outcome 2: Mortality rate among infants age between day 4 to day 365Timepoint: The outcome will be assessed at baseline at the time of initiation of study and then at the end of sixth year of study
- Secondary Outcome Measures
Name Time Method The proportion of hypertension cases who are on treatment, the proportion of hypertension cases who are on treatment & BP is controlled, Proportion of diabetes cases who are on treatment, Proportion of diabetes cases who are on treatment and have achieved blood sugar control, Proportion of persons who were screened for oral and breast cancer among hypertension and diabetes cases who are more than 40 years of age, Treatment gap for common and severe mental health diseases among hypertension and diabetes cases who are more than 40 years of age, Proportion of individuals suffering from sickle cell disease who are consuming Tab. Hydroxyurea, Proportion of pregnant women who are not suffering from severe or moderate anemia on the day of the survey, Proportion of children (6-12 months) who are not suffering from severe or moderately severe anemia on the day of the survey, Cost-effectiveness.Timepoint: Baseline, midline & end line